Spots Global Cancer Trial Database for ganetespib
Every month we try and update this database with for ganetespib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | NCT02389751 | Gastroesophagea... Malignant Neopl... Malignant Neopl... Stage IIA Esoph... Stage IIB Esoph... Stage IIIA Esop... Stage IIIB Esop... Stage IIIC Esop... | Carboplatin Ganetespib Paclitaxel Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | NCT01798485 | Non-Small-Cell ... Non-small Cell ... Non-small Cell ... Non-small Cell ... | Docetaxel Ganetespib | 18 Years - | Synta Pharmaceuticals Corp. | |
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | NCT02192541 | Neoplasms | Ziv-Aflibercept Ganetespib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01962948 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | paclitaxel ganetespib laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | NCT02060253 | HER2-positive B... Male Breast Can... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | ganetespib paclitaxel trastuzumab pertuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | NCT03783949 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Ganetespib Niraparib Carboplatin Paclitaxel Gemcitabine | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | NCT03783949 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Ganetespib Niraparib Carboplatin Paclitaxel Gemcitabine | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| A Phase I/II Study of Ganetespib in Combination With Doxorubicin | NCT02261805 | Cancer Small Cell Lung... | Ganetespib Doxorubicin | 18 Years - | Georgetown University | |
| A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | NCT01798485 | Non-Small-Cell ... Non-small Cell ... Non-small Cell ... Non-small Cell ... | Docetaxel Ganetespib | 18 Years - | Synta Pharmaceuticals Corp. | |
| Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors | NCT00687934 | Solid Tumors | STA-9090 | 25 Years - | Synta Pharmaceuticals Corp. | |
| A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | NCT02637375 | Breast Cancer | Ganetespib Paclitaxel Doxorubicin Cyclophosphamid... | 18 Years - | University of Chicago | |
| A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia | NCT00964873 | Acute Myeloid L... Acute Lymphobla... Blast-phase Chr... AML ALL CML | STA-9090 (ganet... | 18 Years - | Synta Pharmaceuticals Corp. | |
| A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT01485835 | Multiple Myelom... | Ganetespib Bortezomib Dexamethasone | 18 Years - | Emory University | |
| Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma | NCT01590160 | Lung Cancer - M... | Ganetespib | 18 Years - | University College, London | |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | NCT02008877 | Malignant Perip... Sarcoma | ganetespib Sirolimus | 16 Years - | Sarcoma Alliance for Research through Collaboration | |
| A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT01485835 | Multiple Myelom... | Ganetespib Bortezomib Dexamethasone | 18 Years - | Emory University | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders | NCT00858572 | AML CML MDS Myeloproliferat... | STA-9090 (ganet... | 18 Years - | Synta Pharmaceuticals Corp. | |
| A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | NCT02637375 | Breast Cancer | Ganetespib Paclitaxel Doxorubicin Cyclophosphamid... | 18 Years - | University of Chicago | |
| A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) | NCT01562015 | Non Small Cell ... | Ganetespib | 18 Years - | Synta Pharmaceuticals Corp. | |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | NCT02012192 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Ganetespib Paclitaxel | 18 Years - | Medical University Innsbruck | |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | NCT02012192 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Ganetespib Paclitaxel | 18 Years - | Medical University Innsbruck | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) | NCT01039519 | Gastrointestina... | Ganetespib | 18 Years - | Synta Pharmaceuticals Corp. | |
| Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers | NCT01579994 | Advanced Lung C... | Ganetespib (STA... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | NCT02192541 | Neoplasms | Ziv-Aflibercept Ganetespib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders | NCT00858572 | AML CML MDS Myeloproliferat... | STA-9090 (ganet... | 18 Years - | Synta Pharmaceuticals Corp. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
